CYP3A4 and tuberculosis: Paclitaxel is affected by anti‐TB drugs, with rifampin inducing CYP3A4 and P‐glycoprotein (P‐gp) expression, affecting paclitaxel metabolism and efficacy, and promoting P‐gp overexpression through the CK2‐HSP90β‐PXP‐MDR1 signaling pathway and 14–3‐3σ protein interaction with the pregnane X receptor, affecting paclitaxel efficacy [112, 113].